Scientists sequence Nature's antibiotic factory

The genome sequence of Streptomyces coelicolor, one of the family of common soil bacteria that produce more than two thirds of the world's antibiotic medicines, is published in the journal Nature.

Scientists sequence Nature's antibiotic factory

Streptomyces are almost ubiquitous in the soils and are responsible for its familiar 'earthy' smell. The genome data, collected by British scientists from the John Innes Centre and The Wellcome Trust Sanger Institute, is already being used in research that will help develop new types of antibiotics, anticancer agents and other beneficial chemicals.

"At over eight and a half million base pairs it has the largest completely sequenced bacterial genome to date and has a staggering 7825 genes - about half as many as a fruit fly. It is also, like the genomes of flies and humans, a linear DNA molecule, whereas most bacterial genomes are circular."

Dr Stephen Bentley, Project leader at the Wellcome Trust Sanger Institute

New types of antibiotic are urgently needed to help counter the growing threat from so-called 'superbugs', such as MRSA (methicillin-resistant Staphylococcus aureus), that are resistant to conventional treatments. Last month, heart surgery at the Edinburgh Royal Infirmary was suspended after 13 patients in the cardiac unit were found to have MRSA. In 1992, 3 percent of blood poisoning cases were caused by MRSA. By 1999 that proportion had risen to 37 percent and by 2000 nearly 50 percent of cases were caused by the bug

"Remarkably, we are enormously dependent on this common soil bacterium - it produces more than two-thirds of the antibiotics we use today to fight infection, as well as other valuable medical chemicals such as anti-cancer agents. Analysis of the genome has brought valuable new information in the quest to make new antibiotics as well as bringing new insights into the evolution of bacterial chromosomes."

Dr Stephen Bentley

Streptomyces are harmless cousins of the bacteria that cause tuberculosis, leprosy and diphtheria. With the new sequence, many common features of all four genomes have been revealed and there is a real hope that studying these features in Streptomyces will provide new insights into these infamous diseases.

With 7,825 genes, Streptomyces coelicolor is the largest bacterial genome to be sequenced. The project began in 1997, cost £2 million and was funded by the Biotechnology and Biological Sciences Research Council and The Wellcome Trust.

Notes to Editors
  1. The reseach is published today Thursday 9 May 2002 in Nature magazine.
  2. Streptomyces are an almost ubiquitous family of bacteria highly adapted to living in the soil - a nutritionally, physically and biologically complex and variable environment. The Streptomyces genome contains an unprecedented proportion of regulatory genes - predominantly those likely to be involved in responding to external stimuli and stresses.
  3. As well as being used to produce over two thirds of naturally derived antibiotics in current use, Streptomyces are used in the production of many other pharmaceuticals such as anti-tumour agents and immunosuppressants. In all, Streptomyces make over 6,000 different chemicals.
  4. Comparable genomes: Escherichia coli 4,000 genes, yeast 6,000 genes, fruit fly 13,000 genes, worm 18,000, thale cress 26,000 and human about 30,000 genes.
Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7900 607793

Recent News

Low doses of radiation promote cancer-capable cells
New research in mice helps to understand the risks around exposure to low doses of radiation, such as CT scans and x-rays
Chan Zuckerberg Initiative boosts Human Cell Atlas research at the Sanger Institute
Seed Networks projects will focus on specific tissues, such as the thymus, lung, liver, kidney and immune system
Widely-available antibiotics could be used in the treatment of ‘superbug’ MRSA
Genomic analysis shows that a significant number of strains are susceptible to penicillin combined with clavulanic acid